Market Research Logo

Cell Therapy Manufacturing Market (2nd Edition), 2018-2030

Cell Therapy Manufacturing Market (2nd Edition), 2018-2030

Cell-based therapies have gained significant attention in the overall biopharmaceutical industry. The personalized nature of these treatment options render them highly specific and, according to a number of clinical studies, safe and efficacious. Such therapies are considered to possess the potential to address various unmet medical needs associated with the treatment of several types of physiological disorders and clinical conditions. A number of pharmaceutical companies and investors have already invested significant capital towards the development and commercialization of such products. Around 20 such therapies have been approved; recent approvals include Alofisel® (2018), YESCARTA® (2017) and Kymriah® (2017). It is also worth highlighting that over 500 cell-based therapy candidates are in different stages of clinical development, and are being evaluated in more than 1,000 active clinical studies across various regions of the globe.

The growing number of cell therapy candidates, coupled to their rapid progression through various phases of clinical development, continues to create an increasing demand for facilities that offer manufacturing services for these complex therapies. There is a wide array of industry players, including well-established companies, mid-sized firms and start-ups, as well as academic institutes that are significantly contributing to the production of GMP grade cell therapies. In addition, several players offer novel technology solutions, aimed at improving and upgrading existing cell-based therapies and their manufacturing processes. Most of these players have signed multiple partnerships / collaborations with an aim to optimize, scale-up and expand the capabilities for the production of cell-based therapies. Additionally, stakeholders have received significant support from governments worldwide, in terms of funding and establishment of consortiums, to accelerate the transition of these therapies from laboratories to clinics. Looking at the evolutionary trend so far, we believe that the cell therapy manufacturing market is poised to steadily grow, driven by a robust pipeline of therapy candidates and technological advances aimed to mitigate challenges posed by the conventional methods of production.

SCOPE OF THE REPORT
The “Cell Therapy Manufacturing Market (2nd Edition), 2018-2030” report provides an extensive study of the rapidly growing market of cell therapy manufacturing, focusing on contract manufacturers, as well as cell therapy developers with in-house manufacturing facilities. The study presents an in-depth analysis of various organizations that are engaged in this domain across different regions of the globe. Amongst other elements, the report includes:

A review of the current status of the market with respect to key players, along with information on the location of their manufacturing facilities, scale of production, type of cells manufactured (immune cells (such as T cells, dendritic cells, NK cells), stem cells (such as adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), purpose of production (fulfilling in-house requirements / as a contract service provider), type of organization (industry / non-industry), source of cell-based therapies (autologous / allogeneic), cGMP regulatory compliance, and availability of fill / finish services for cell-based therapies.

A discussion on roadmaps published by different agencies across the globe to provide strategies to advance cell therapy manufacturing.

Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services for cell-based therapies; each profile presents an overview of the company, information on its manufacturing facilities, and recent collaborations.

A discussion on the role of non-profit organizations that have aided in the advancement of cell-based therapies, as well as manufacturing processes.

Detailed information on the role of automation technologies in improving current manufacturing methods, along with a qualitive comparative analysis of cost differences between manual and automated processes.

An analysis of the recent collaborations (signed since 2014) focused on the manufacturing of cell-based therapies; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, and scale of operation (clinical and / or commercial).

An estimate of the overall installed capacity for manufacturing cell-based therapies of various organizations, based on information reported by industry stakeholders in the public domain (wherever available) and affiliated data collated via both secondary and primary research. The analysis highlights the distribution of the global capacity of industry and non-industry players on the basis of scale of operation (clinical and commercial), regions (North America, EU and Asia Pacific) and size of the organization (small-sized, mid-sized and large-sized organizations).

An analysis of the various factors that are likely to influence the pricing of cell-based therapies, featuring different models / approaches that may be adopted by manufacturers to decide the prices of these therapies.

An in-depth analysis of the cell-based therapy manufacturers, featuring three schematic representations; these include [A] a three dimensional grid analysis, representing the distribution of cell-based therapy manufacturers on the basis of the type of cells manufactured, scale of operation and purpose of production (in-house operations / contract manufacturing services), [B] a logo landscapes of cell therapy manufacturers based on the type of cells manufactured, geographical location (North America, EU and Asia Pacific) and the type / size of organization (non-industry players, and small-sized, mid-sized and large companies), and [C] a schematic world map representation, highlighting the geographical locations of cell therapy manufacturing facilities of industry and non-industry stakeholders.

A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry’s evolution, under a comprehensive SWOT framework. It also includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall market.

A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in development and / or manufacturing of cell-based therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as increase in number of clinical studies, target patient population, anticipated adoption of cell-based therapies and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2018-2030. In addition, to account for the uncertainties associated with the manufacturing of cell-based therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with
Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy)
Tim Oldham (Chief Executive Officer, Cell Therapies)
Gerard MJ Bos (Chief Executive Officer, CiMaas)
Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. During our research, we identified over 145 organizations that are actively involved in manufacturing cell-based therapies. The current market landscape features a mix of industry players and non-industry players. Amongst the industry players, over 45 are large or mid-sized firms (with more than 50 employees) involved in the production of cell-based therapies. Further, the growing demand for such therapy products has spurred the establishment of several start-ups as well; examples of organizations that have recently entered the domain include (in the order of year of establishment) Gates Biomanufacturing Facility, IncoCell Tianjin, Mustang Bio, Nikon CeLL innovation, Advent Bioservices, Laboratory for Cell and Gene Medicine (University of Stanford), Cell Therapy Manufacturing Facility (MedStar Georgetown University Hospital), YPOSKESI and The Elisa Linton Center for Rare Disease Therapies.

2. More than 60 non-industry players, including universities, research institutes and hospitals, are currently involved in manufacturing of cell-based therapies. Examples of such organizations include (in alphabetical order) Biological and Cellular GMP Manufacturing Facility (City of Hope), Cell Therapy Facility (UMC Utrecht), Cellular Therapy Integrated Services (Case Western Reserve University), Dana-Farber / Harvard Cancer Center Cell Manipulation Core, Interdisciplinary Stem Cell Institute, Miller School of Medicine (University of Miami), Molecular and Cellular Therapeutics (University of Minnesota), Scottish National Blood Transfusion Service Cellular Therapy Facility, The Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center and Upstate Stem Cell cGMP Facility (University of Rochester).

3. As majority of cell therapy products are in the clinical phases of development, most manufacturing facilities presently have the capacity to support clinical scale production requirements. However, some players (53) have already developed / are developing commercial scale capacity for the production of cell therapies. Examples include (in alphabetical order) 3P Biopharmaceuticals, apceth Biopharma, BioNTech Innovative Manufacturing Services, Brammer Bio, CELLforCURE, Cognate BioServices, Guy's and St Thomas' Facility, Lonza, MaSTherCell and SOTIO.

4. More than 60% of the organizations engaged in this domain, possess the capability to manufacture stem cell therapies (including induced pluripotent stem cells) and immune cell-based therapies (such as T-cell immunotherapies and dendritic cell cancer vaccines). Of the total, more than 50 players claim to have the facilities for manufacturing both adult stem cell therapies and immunotherapies . Examples include (in alphabetical order) Center for Gene and Cell Processing (Takara Bio), Cryosite, Centre for Stem Cells Research, Cooperative Research Centre for Cell Therapy Manufacturing, Gamida Cell, GC Cell, MEDINET and Pharmicell.

5. Although the current market landscape is dominated by contract manufacturers (97 manufacturers), some well-established cell therapy developers have set up in-house manufacturing capabilities to support proprietary requirements for cGMP grade cells. Examples of such organizations include (in alphabetical order) Adaptimmune, Argos Therapeutics, Cell Medica, Cellular Biomedicine Group, Kite Pharma (a subsidiary of Gilead Sciences) and Sumitomo Dainippon Pharma. In addition, we identified over 24 organizations that not only manufacture cell-based therapies for their own use, but also offer their capabilities by providing contract services to other players in this domain. Prominent examples include (in alphabetical order) Center for Cell and Gene Therapy, Baylor College of Medicine, Children's GMP / GMP facility (St. Jude Children's Research Hospital), Cook Myosite, FUJIFILM Cellular Dynamics, John Goldmann Centre for Cellular Therapy (Imperial College London), MolMed and Oxford BioMedica.

6. Although, the global installed capacity for cell therapy production is well-distributed between major regions across the globe, we identified that approximately 41% of 195 manufacturing facilities are located in Europe; this is followed by North America, where approximately 38% of the world's cell therapy manufacturing facilities are based. Other emerging pockets for cell therapy manufacturing include Australia, China, Japan, Singapore, South Korea and Israel; it is wort highlighting that facilities in these regions primarily cater to markets in the Asia-Pacific region only.

7. Automation is considered to be a key enabler in this domain and many service providers offering solutions to reduce manual effort have emerged. We identified close to 15 companies that are actively providing support to cell therapy developers to improve their manufacturing process; these include (in alphabetical order) Berkeley Lights, Cesca Therapeutics, Ferrologix, FluDesign Sonics, GE Healthcare and Terumo BCT. Further, we identified five players, namely (in alphabetical order) Fraunhofer Institute for Manufacturing Engineering and Automation IPA, Invetech, KMC Systems, Mayo Clinic Center for Regenerative Medicine and RoosterBio, that offer consultancy solutions related to automation.

8. Over 150 collaborations have been inked in this domain since 2014; of these, 32% were observed to have been associated with the supply of cell-based therapy products for clinical trials. It is worth highlighting that in the last three years, there has been a marked increase (from 32 in 2016 to 49 in 2018) in number of collaborations focused on upgrading existing manufacturing processes. Examples of the companies that have entered into such deals include (in alphabetical order) ATMI, GE Healthcare, Hielscher Ultrasonics, Invetech, Pall, Reinnervate, Terumo BCT and Tokyo Electron. Other type of collaborations that were observed include additional services agreement (24%), joint venture (9%) and acquisitions (3%).

9. Driven by the rapidly evolving pipeline of advanced therapies and the increasing adoption of automated technologies, the cell therapy manufacturing market is expected to grow at an accelerated pace. T-cell therapies, followed by dendritic cell and tumor cell-based cancer vaccines, currently capture the largest shares in the market. This trend is unlikely to change during the forecast period. Further, autologous cell therapies are expected to capture a significant share of the market, given the fact that such therapies have lesser side effects (lower risk of graft rejections), and have high prices which directly translate into high revenue generation potential.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various emerging trends in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the cell-based therapy manufacturing market in the short to mid-term, and long term.

Chapter 3 provides a general introduction to the cell-based therapies and ATMPs. It includes a detailed discussion on the manufacturing process of cell-based therapies, associated challenges, and applications of currently available cell therapies. It also provides information on the manufacturing models (centralized and decentralized) that are being considered for the production of cell-based therapies, along with a discussion on their advantages and disadvantages. Further, it provides details on the scalability of these cell-based therapies. The chapter also includes a brief overview on the role of automation and supply chain management with respect to cell-based therapies.

Chapter 4 features a list of all the contract service providers / in-house manufacturers that are actively involved in the manufacturing of cell-based therapies. It provides information on the type of organizations and the geographic location of their facilities, and details on their cell-based therapy manufacturing capabilities, specifically focusing on scale of operation, type of cells manufactured, purpose of manufacturing (in-house requirement / contract manufacturing), source of cells (autologous / allogeneic) and availability of fill / finish services.

Chapter 5 provides a detailed description on the regulatory landscape related to cell therapies across various geographies, such as the US, Europe and other regions. Further, it presents an analysis of the manufacturing facilities on basis of the certifications awarded (for manufacturing cell-based therapies) to individual sites by various regulatory bodies across the globe.

Chapter 6 describes the strategies that are likely to be adopted to accelerate the translation of cell-based therapies from laboratory to clinics. It provides details on roadmaps published by different organizations in various geographies, specifically in the US.

Chapter 7 discusses the role of automation technologies that are likely to optimize the current manufacturing practices with the use of closed and single use systems. Further, it features a roadmap that provides information on the steps to develop automation devices. It also presents a qualitive analysis of the cost incurred while manufacturing cell-based therapies using manual versus automated manufacturing approaches. In addition, it features a list of organizations that offer automated technologies for manufacturing operations or provide services to therapy developers to automate their production processes.

Chapter 8 offers detailed profiles of industry players that offer contract manufacturing services at the clinical and / or commercial scales. Each profile provides a brief overview of the company, details on its manufacturing capabilities and facilities, and the relevant collaborations that have been inked over the last few years.

Chapter 9 offers profiles of the non-industry players that offer contract manufacturing services for cell therapies. Each profile provides a brief overview of the organization, and details on manufacturing capabilities and facilities.

Chapter 10 discusses the role of non-profit organizations in this domain. It provides a list of organizations that are actively involved in the development and production of cell-based therapies, across different global regions. Further, it includes profiles of organizations that provide financial and / or technological support to cell therapy manufacturers and developers. Additionally, the chapter provides information on various international / national societies that help in disseminating knowledge about the advancement of these therapies to the general community.

Chapter 11 features an elaborate analysis and discussion of the various collaborations and partnerships that have been inked amongst players in this market. It includes a brief description on the various types of partnership models (which include manufacturing agreements, technology upgrade and manufacturing process development and testing agreements, additional services agreements, joint ventures and acquisitions) that are employed by stakeholders in this domain, and analysis on the trend of partnerships inked since 2014. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to the manufacturing of cell-based therapies. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 12 features a comprehensive analysis of the overall installed capacity of cell-based therapy manufacturers. The analysis is based on meticulous data collection of reported capacities, via both secondary and primary research, of various small-sized, mid-sized and large-sized companies, and non-industry players distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the cell-based therapy production capabilities of organizations across different types of organization (industry and non-industry), scale of operation (clinical and commercial), geographies (North America, EU, Asia Pacific and the rest of the world) and size of the organization (small-sized, mid-sized and large-sized organizations).

Chapter 13 highlights our views on the various factors, including manufacturing costs, that may be taken into consideration while pricing cell-based therapies. It features discussions on different pricing models / approaches, which a manufacturer may choose to adopt to decide the price of its proprietary products.

Chapter 14 presents a comprehensive market forecast analysis, highlighting the likely growth of the cell therapy manufacturing market till the year 2030. We have segregated the opportunity by scale of operation (clinical and commercial), type of cell therapy (T-cell immunotherapies, dendritic cell-based therapies, stem cell therapies and other ATMPs), source of cells (autologous and allogeneic) and geography (North America, EU and Asia Pacific).

Chapter 15 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of cell-based therapy manufacturers on the basis of type of cells manufactured, scale of production and purpose of manufacturing (fulfilling in-house requirement / contract service provider). In addition, it consists of two logo landscapes, representing the distribution of cell-based therapy manufacturers based on the type of cells manufactured (immune cells and stem cells), geographical regions (North America, EU and Asia Pacific) and the type / size of organization (non-industry, small-sized, mid-sized and large companies). The chapter also consists of two schematic world map representations to highlight the locations of various cell-based therapy manufacturing facilities across different continents.

Chapter 16 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of cell therapy manufacturing, under a comprehensive SWOT framework.

Chapter 17 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 18 presents insights from the survey conducted for this study. We invited over 100 stakeholders involved in the development and / or manufacturing of different types of cell therapies. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 19 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy), Tim Oldham (Chief Executive Officer, Cell Therapies), Gerard MJ Bos (Chief Executive Officer, CiMaas), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing) and Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi)

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 21 is an appendix, which presents the list of companies and organizations that have been mentioned in the report.

LIST OF COMPANIES / LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report.
1. 3P Biopharmaceuticals
2. A2 Healthcare
3. Accellta
4. Acerta Pharma
5. Adaptimmune
6. Adva Biotechnology
7. Advanced Cell Therapy Laboratory, Yale School of Medicine
8. Advanced Regenerative Manufacturing Institute
9. Advent Bioservices
10. Agios Pharmaceuticals
11. Ajinomoto
12. Akron Biotech
13. Alberta Cell Therapy Manufacturing, University of Alberta
14. Allele Biotechnology & Pharmaceuticals
15. Alliance for Regenerative Medicine
16. AlloSource
17. Altor BioScience
18. American Productivity & Quality Center
19. American Society of Gene and Cell Therapy
20. American Society of Mechanical Engineers
21. Amgen
22. Amsterdam Biotherapeutics Unit
23. Andalusian Initiative for Advanced Therapies
24. Angiocrine Bioscience
25. Anterogen
26. Aokai (Suzhou) Biomedical
27. apceth Biopharma
28. Argos Therapeutics
29. ARIAD Pharmaceuticals
30. Asahi Glass Company
31. Asterias Biotherapeutics
32. AstraZeneca
33. Asymptote
34. Atara Biotherapeutics
35. Athersys
36. Atlantic Bio GMP
37. ATVIO Biotechnology
38. Australasian Gene and Cell Therapy Society
39. Austrian Network for Gene Therapy
40. Autolus
41. Azellon Cell Therapeutics
42. Bavarian Nordic
43. Bayer
44. Be The Match BioTherapies
45. Bellicum Pharmaceuticals
46. Berkeley Lights
47. Bio Elpida
48. BioCision
49. Bioinova
50. BioLife Solutions
51. Biological and Cellular GMP Manufacturing Facility, City of Hope
52. biologistex CCM
53. BioNTech Innovative Manufacturing Services
54. Biosafe Group
55. bluebird bio
56. Boehringer Ingelheim
57. Bone Therapeutics
58. Brammer Bio
59. Bristol-Myers Squibb
60. British Society for Gene and Cell Therapy
61. Caladrius Biosciences
62. California Institute of Regenerative Medicine
63. Cancer Research UK
64. Capricor Therapeutics
65. CardioCell
66. Celgene
67. Cell and Gene Therapy Catapult
68. Cell Manipulation Core, Dana-Farber / Harvard Cancer Center
69. Cell Medica
70. Cell Tech Pharmed
71. Cell Therapies
72. Cell Therapy and Regenerative Medicine, University of Utah
73. Cell Therapy Facility, UMC Utrecht
74. Cell Therapy Manufacturing Cooperative Research Center
75. Cell Therapy Suite, University of Birmingham
76. Cellab
77. CellCAN
78. Cellectis
79. CELLforCURE
80. Cellin Technologies
81. Cells Cure Foundation
82. Cells for Sight, Stem Cell Therapy Research Unit, University College London
83. Cellular Biomedicine Group
84. Cellular Therapeutics
85. Cellular Therapy Core, University of Texas
86. Cellular Therapy Integrated Services, Case Western Reserve University
87. Celyad
88. Censo Biotechnologies
89. Center for Biomedical Engineering and Advanced Manufacturing, McMaster University
90. Center for Cell and Gene Therapy, Baylor College of Medicine
91. Center for Gene and Cell Processing, Takara Bio
92. Center for International Blood and Marrow Transplant Research
93. Centre for Biological Engineering, Loughborough University
94. Centre for Cell and Vector Production
95. Centre for Cell Manufacturing Ireland, NUI Galway
96. Centre for Commercialization of Regenerative Medicine
97. Centre for Stem Cell Research
98. Centre for Commercialization of Cancer Immunotherapy (C3i)
99. Centre multidisciplinaire de développement du génie tissulaire
100. Centre of Genomics and Policy, McGill University
101. Cesca Therapeutics
102. Chemometec
103. Chiesi Farmaceutici
104. Children’s Medical Research Institute
105. Children's GMP, St. Jude Children's Research Hospital
106. China Life Health Industry Group
107. China Regenerative Medicine International
108. CiMaas
109. City of Hope Alpha Clinic for Cell Therapy
110. Clinical Biomanufacturing Facility, University of Oxford
111. Clinical Cell and Vaccine Production Facility
112. Clinical Research Facility, South London and Maudsley
113. Closed Cell Systems
114. Cognate BioServices
115. Commonwealth Scientific and Industrial Research Organization
116. Cook MyoSite
117. CRISPR Therapeutics
118. Cryoport
119. Cryosite
120. CureCell
121. Cynata Therapeutics
122. Cytonome
123. Cytori Therapeutics
124. CyTuVax
125. DanDrit Biotech
126. DCPrime
127. Dendreon
128. DiscGenics
129. Eli Lilly
130. EMERCell
131. Emory Personalized Immunotherapy Core
132. European Bank for induced pluripotent Stem Cells
133. European Society of Gene and Cell Therapy
134. Federal Economic Development Agency for Southern Ontario
135. Ferrologix
136. Fibrocell
137. Finnish Gene Therapy Society
138. Fisher BioServices
139. FloDesign Sonics
140. Fortuna Fix
141. Fosun Pharma
142. Foundation for the Accreditation of Cellular Therapy
143. Foundation of Croatian Association for Regenerative Medicine and Stem Cell Therapy
144. Fraunhofer Institute for Cell Therapy and Immunology IZI
145. French Society of Cellular and Gene Therapy
146. Froceth
147. FUJIFILM
148. FUJIFILM Cellular Dynamics
149. Gamida Cell
150. Gates Biomanufacturing Facility
151. GC Cell
152. GE Healthcare
153. GenCure
154. Gene and Cell Therapy Lab, Institute of Translational Health Sciences
155. Genentech
156. Georgia Institute of Technology
157. Georgia Research Alliance
158. German Gene Therapy Society
159. Gilead Sciences
160. GlaxoSmithKline
161. Glycostem Therapeutics
162. GPB Scientific
163. Gradalis
164. Great Ormond Street Hospital Cellular Therapy Laboratories, University College London
165. Guy's and St Thomas' Facility
166. Haematological Sciences, Institute of Cellular Medicine
167. Harvard University Stem Cell Institute
168. Health Sciences Authority
169. Hielscher Ultrasonics
170. Histocell
171. Hitachi Chemical Advanced Therapeutics Solutions
172. Holostem Terapie Avanzate
173. Hospital of University of Pennsylvania
174. Houston Methodist Hospital Foundation
175. Houston Methodist Institute of Technology, Innovation and Education
176. Houston Methodist Research Institute
177. Human Islet and Cellular Transplant Facility
178. Human Stem Cells Institute
179. Immatics Biotechnologies
180. ImmunoCellular Therapeutics
181. Immunocore
182. Immunovative Therapies
183. IncoCell Tianjin
184. Innovate UK
185. Innovative Cellular Therapeutics
186. IntelliCell BioSciences
187. Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami
188. International Cellular Medicine Society
189. International Society for Cancer Gene Therapy
190. International Society for Cellular Therapy
191. International Society for Stem Cell Research
192. International Stem Cell Corporation
193. Invetech
194. Iovance Biotherapeutics
195. IQVIA Stem Cell Center
196. Irish Society for Gene and Cell Therapy
197. Irish Stem Cell Foundation
198. Israeli Society for Gene and Cell Therapy
199. Isto Biologics
200. Japan Society for Gene Therapy
201. Japan Tissue Engineering
202. Jazz Pharmaceuticals
203. JCR Pharmaceuticals
204. John Goldmann Centre for Cellular Therapy, Imperial College London
205. Juno Therapeutics
206. JW CreaGene
207. Kawasaki Heavy Industries
208. KBI Biopharma
209. Kiadis Pharma
210. Kids Research Institute
211. Kite Pharma
212. KMC Systems
213. Kolon TissueGene
214. Korean Society of Gene and Cell Therapy
215. Laboratory for Cell and Gene Medicine, University of Stanford
216. Lexicon Pharmaceuticals
217. Lion TCR
218. Lonza
219. Maisonneuve-Rosemont Hospital
220. Marken
221. MaSTherCell
222. Mayo Clinic Center for Regenerative Medicine
223. MedCision
224. Medigene
225. MEDINET
226. Medipost
227. Medistem Panama (Stem Cell Institute)
228. MedPost
229. MedStar Georgetown University Hospital
230. Merck
231. Mesoblast
232. Michael Smith Laboratories, University of British Columbia
233. Millennium Pharmaceuticals
234. Millipore Sigma
235. Miltenyi Biotec
236. MNX Global Logistics
237. Moffitt Cancer Center
238. Molecular and Cellular Therapeutics, University of Minnesota
239. MolMed
240. Mustang Bio
241. Nantes University Hospital
242. National Cell Manufacturing Consortium
243. National Centre for Biomedical Engineering Sciences
244. National Eye Institute
245. National Gene Vector Laboratory
246. National Institute of Health Research
247. National Institute of Standards and Technologies
248. National Stem Cell Foundation
249. National Stem Cell Foundation of Australia
250. Neon Therapeutics
251. Netherlands Cancer Institute
252. Networks of Centres of Excellence
253. Neuralstem
254. NewLink Genetics
255. NHSBT Birmingham
256. Nikon
257. Nikon CeLL innovation
258. Nohla Therapeutics
259. Northwest Biotherapeutics
260. Norwegian Radium Hospital
261. Novadip
262. Novartis
263. NuVasive
264. Octane Medical Group
265. Oncobiomed
266. Ontario Institute of Regenerative Medicine
267. Onyx Pharmaceuticals
268. Opexa Therapeutics
269. Orchard Therapeutics
270. Orgenesis
271. Orthofix
272. Ospedale Pediatrico Bambino Gesù
273. Ottawa Hospital Research Institute, University of Ottawa
274. Oxford BioMedica
275. Oxford MEStar
276. Pall Corporation
277. PAREXEL
278. PCI Services
279. PCT Cell Therapy Services
280. Peter Couche Foundation
281. Peter MacCallum Cancer Centre
282. Pfizer
283. PharmaBio
284. PharmaCell
285. Pharmicell
286. Pluristem Therapeutics
287. Praxis Pharmaceutical
288. Production Assistance for Cellular Therapies
289. Promethera Biosciences
290. Provia Laboratories
291. Puma Biotech
292. Q-GEN Cell Therapeutics, QIMR Berghofer Medical Research Institute
293. Rayne Cell Therapy Suite, King's College London
294. Regenerative Medicine Foundation
295. Regenerative Medicine Institute
296. Regenesys
297. Regeneus
298. Reliance Life Sciences
299. ReNeuron
300. RepliCel
301. Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation
302. Riyadh Pharma
303. Robertson Clinical and Translational Cell Therapy, Duke University
304. Roche Diagnostics
305. Rooster Bio
306. Roslin Cells
307. Roswell Park Cancer Institute
308. Royal Free Hospital, Centre for Cell and Gene Tissue Therapeutics
309. Royal Prince Alfred Hospital
310. Saint-Gobain
311. SanBio
312. Sartorius Stemdim
313. SAVSU Technologies
314. Scinogy
315. Scottish Centre for Regenerative Medicine
316. Scottish National Blood Transfusion Service Cellular Therapy Facility
317. Servier
318. Shanghai Sunway Biotech
319. Shenzhen SiBiono GeneTech
320. Shibuya Corporation
321. Sistemic
322. Smilow Translational Research Center
323. Smith & Nephew
324. SOTIO
325. Spanish Society of Gene and Cell Therapy
326. Spark Therapeutics
327. Stage Cell Therapeutics
328. Stanford Children's Health, Stanford Health Care
329. Stanford School of Medicine
330. Stemedica Cell Technologies
331. Sumitomo Dainippon Pharma
332. Swedish Society for Gene and Cell Therapy
333. Sydney Cell and Gene Therapy
334. SynGen
335. Takeda Pharmaceutical
336. TAP Biosystems
337. TargetAMD
338. TC Biopharm
339. T-Cell Factory
340. Terumo
341. Terumo BCT
342. TESARO
343. Texas Children’s Hospital
344. Texas Medical Center
345. The Children’s Hospital at Westmead
346. The Elisa Linton Center for Rare Disease Therapies
347. The Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
348. The Netherlands Society of Gene and Cell Therapy
349. The New York Stem Cell Foundation
350. The Ottawa Hospital Research Institute
351. The Philip S Orsino Facility for Cell Therapy, Princess Margaret Hospital
352. The University of Texas Health Science Center
353. Therapeutic Cell Production Core, Seattle Children's Hospital
354. Thermo Fisher Scientific
355. ThermoGenesis
356. TiGenix
357. Tokyo Electron
358. TrakCel
359. Trinity Partners
360. Turkish Society for Gene and Cell Therapy
361. TVAX Biomedical
362. TxCell
363. Tyne Hospitals NHS Foundation Trust
364. UC Davis GMP Laboratory
365. UCLA Human Gene and Cell Therapy
366. UCLA-UCI Alpha Stem Cell Clinic
367. UK Stem Cell Foundation
368. University Hospital Basel
369. University Medical Center Groningen
370. University of California
371. University of Leeds
372. University of Manchester
373. University of Newcastle
374. University of North Carolina Lineberger Comprehensive Cancer Center
375. University of Tennessee
376. University of Wisconsin–Madison
377. Upstate Stem Cell cGMP Facility, University of Rochester
378. Vaccinogen
379. Valeant Pharmaceuticals
380. Vecura, Karolinska University Hospital
381. Vericel
382. Vineti
383. Vitruvian Networks
384. VivaBioCell
385. Waisman Biomanufacturing
386. Westmead Hospital
387. Westmead Millennium Institute
388. World Courier
389. WuXi Advanced Therapies
390. WuXi AppTec
391. Wyeth
392. Xellbiogene
393. YposKesi
394. Zelluna Immunotherapy


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. An Introduction to Cell-based Therapies
3.2.1. Comparison of Cell-based Therapies and Other Biotechnology Products
3.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
3.2.3. Current Market Landscape
3.3. An Overview to Cell Therapy Manufacturing
3.4. Cell Therapy Manufacturing Models
3.4.1. Centralized Manufacturing Model
3.4.2. Decentralized Manufacturing Model
3.5. Scalability of Cell Therapy Manufacturing Processes
3.5.1. Scale-up
3.5.2. Scale-out
3.6. Types of Cell Therapy Manufacturers
3.7. Key Challenges for Manufacturing Cell Therapies
3.8. Important Factors for Cell Therapy Manufacturing
3.8.1. Characterization
3.8.2. Cost of Goods
3.9. Automation of Cell Therapy Manufacturing Processes
3.10. Supply Chain for Cell Therapy Manufacturing
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Cell Therapy Manufacturers: Overall Market Landscape
4.2.1. Distribution by Location of Headquarters
4.2.2. Distribution by Location of Manufacturing Facility
4.2.3. Distribution by Type of Cells Manufactured
4.2.4. Distribution by Purpose of Production
4.2.5. Distribution by Scale of Operation
4.2.6. Distribution by Source of Cells
4.2.7. Distribution by Type of Cell Cultures
4.3. Cell Therapy Manufacturing: Role of Logistics Service Providers
5. REGULATORY LANDSCAPE
5.1. Chapter Overview
5.2. Current Scenario
5.2.1. Regulatory System in the US
5.2.2. Regulatory System in Europe
5.2.3. Regulatory System in Japan
5.2.4. Conditional Approvals
5.3. Accreditations for Cell Therapy Manufacturing
5.3.1. Information on Facility Approvals Granted by Various Regulatory Authorities
5.4. Guidelines for Manufacturing Cell-based Therapies
5.5. Existing Challenges
5.5.1. Variability in Regulatory Guidelines across Different Geographies
6. ROADMAPS: POTENTIAL STRATEGIES TO OVERCOME EXISTING CHALLENGES
6.1. Chapter Overview
6.2. Roadmap for the US
6.2.1. Cell Processing
6.2.2. Cell Preservation, Distribution and Handling
6.2.3. Process Automation and Data Analytics
6.2.4. Process Monitoring and Quality Control
6.2.5. Standardization and Regulatory Support
6.2.6. Workforce Development
6.2.7. Supply Chain and Transport Logistics
6.3. Roadmaps for Other Geographies
6.3.1. Europe
6.3.2. Asia Pacific
7. AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING
7.1. Chapter Overview
7.2. Automation of Cell Therapy Processes
7.2.1. Closed Systems
7.2.2. Single-use Systems
7.2.3. Modular Systems
7.3. Case Study: A Roadmap for Developing an Automated Device
7.4. GMP-in-a-Box
7.5. List of Automation Service Providers
7.6. Comparative Analysis of Manual and Automated Processes
8. CELL THERAPY MANUFACTURING: INDUSTRY PLAYERS
8.1. Chapter Overview
8.2. Market Landscape in the US
8.2.1. Brammer Bio
8.2.1.1. Company Overview
8.2.1.2. Service Portfolio
8.2.1.3. Manufacturing Capabilities
8.2.1.4. Partnerships
8.2.2 Cognate BioServices
8.2.2.1. Company Overview
8.2.2.2. Service Portfolio
8.2.2.3. Manufacturing Capabilities
8.2.2.4. Partnerships
8.2.3. FUJIFILM Cellular Dynamics
8.2.3.1. Company Overview
8.2.3.2. Service Portfolio
8.2.3.3. Manufacturing Capabilities
8.2.3.4. Partnerships
8.2.4. KBI Biopharma
8.2.4.1. Company Overview
8.2.4.2. Service Portfolio
8.2.4.3. Manufacturing Capabilities
8.2.5 PCT, a Hitachi Group Company
8.2.5.1. Company Overview
8.2.5.2. Service Portfolio
8.2.5.3. Manufacturing Capabilities
8.2.5.4. Partnerships
8.2.6. Waisman Biomanufacturing
8.2.6.1. Company Overview
8.2.6.2. Service Portfolio
8.2.6.3. Manufacturing Capabilities
8.2.6.4. Partnerships
8.3. Market Landscape in Europe
8.3.1. BioNTech Innovative Manufacturing Services
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.3. Manufacturing Capabilities
8.3.1.4. Partnerships
8.3.2. Cell and Gene Therapy Catapult
8.3.2.1. Company Overview
8.3.2.2. Service Portfolio
8.3.2.3. Manufacturing Capabilities
8.3.2.4. Partnerships
8.3.3. CELLforCURE
8.3.3.1. Company Overview
8.3.3.2. Service Portfolio
8.3.3.3. Manufacturing Capabilities
8.3.3.4. Partnerships
8.3.4. Lonza
8.3.4.1. Company Overview
8.3.4.2. Service Portfolio of Lonza
8.3.4.3. Service Portfolio of Lonza Netherlands
8.3.4.4. Manufacturing Capabilities
8.3.4.5. Partnerships
8.3.5. MaSTherCell
8.3.5.1. Company Overview
8.3.5.2. Service Portfolio
8.3.5.3. Manufacturing Capabilities
8.3.5.4. Partnerships
8.3.6. Roslin Cell Therapies
8.3.6.1. Company Overview
8.3.6.2. Service Portfolio
8.3.6.3. Manufacturing Capabilities
8.3.6.4. Partnerships
8.4. Market Landscape in Asia Pacific
8.4.1. Cell Therapies
8.4.1.1. Company Overview
8.4.1.2. Service Portfolio
8.4.1.3. Manufacturing Capabilities
8.4.1.4. Partnerships
8.4.2. Cryosite
8.4.2.1. Company Overview
8.4.2.2. Service Portfolio
8.4.2.3. Manufacturing Capabilities
8.4.2.4. Partnerships
8.4.3. Japan Tissue Engineering (J-TEC)
8.4.3.1. Company Overview
8.4.3.2. Service Portfolio
8.4.3.3. Manufacturing Capabilities
8.4.3.4. Partnerships
8.4.4. MEDINET
8.4.4.1. Company Overview
8.4.4.2. Service Portfolio
8.4.4.3. Manufacturing Capabilities
8.4.5. Nikon CeLL innovation
8.4.5.1. Company Overview
8.4.5.2. Service Portfolio
8.4.5.3. Manufacturing Capabilities
8.4.5.4. Partnerships
8.4.6. WuXi AppTec
8.4.6.1. Company Overview
8.4.6.2. Service Portfolio
8.4.6.3. Manufacturing Capabilities
8.4.6.4. Partnerships
9. CELL THERAPY MANUFACTURING: NON-INDUSTRY PLAYERS
9.1. Chapter Overview
9.2. Center for Cell and Gene Therapy, Baylor College of Medicine
9.2.1. Overview
9.2.2. Operating Segments
9.2.3. Service Portfolio
9.2.4. Manufacturing Facilities and Capabilities
9.3. Centre for Cell Manufacturing Ireland, National University of Ireland
9.3.1. Overview
9.3.2. Service Portfolio
9.3.3. Manufacturing Facilities and Capabilities
9.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania
9.4.1. Overview
9.4.2. Service Portfolio
9.4.3. Manufacturing Facilities and Capabilities
9.5. Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
9.5.1. Overview
9.5.2. Service Portfolio
9.5.3. Manufacturing Facilities and Capabilities
9.6. Laboratory for Cell and Gene Medicine, Stanford University
9.6.1. Overview
9.6.2. Manufacturing Facilities and Capabilities
9.7. Molecular and Cellular Therapeutics, University of Minnesota
9.7.1. Overview
9.7.2. Service Portfolio
9.7.3. Manufacturing Facilities and Capabilities
9.8. Newcastle Cellular Therapies Facility, Newcastle University
9.8.1. Overview
9.8.2. Service Portfolio
9.8.3. Manufacturing Facilities and Capabilities
9.9. Rayne Cell Therapy Suite, King’s College London
9.9.1. Overview
9.9.2. Manufacturing Facilities and Capabilities
9.10. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre of Regenerative Medicine
9.10.1. Overview
9.10.2. Manufacturing Facilities and Capabilities
9.11. Sydney Cell and Gene Therapy
9.11.1. Overview
9.11.2. Manufacturing Facilities and Capabilities
10. ROLE OF NON-PROFIT ORGANIZATIONS
10.1. Chapter Overview
10.2. Cell Therapy Manufacturing: Non-Profit Organizations
10.2.1. CellCAN
10.2.2. Cell Therapy Manufacturing Cooperative Research Center
10.2.3. National Cell Manufacturing Consortium
10.2.4. California Institute of Regenerative Medicine
10.3. Cell Therapy Manufacturing: International Societies
11. RECENT DEVELOPMENTS
11.1. Chapter Overview
11.2. Partnership / Collaboration Models
11.3. Cell Therapy Manufacturing: List of Partnerships
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership Model
11.3.3. Analysis by Year and Type of Partnership Model
11.3.4. Analysis by Type of Cells
11.3.5. Most Active Players: Analysis by Number of Partnerships
11.3.6. Regional Distribution
12. CAPACITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology for Industry Players
12.2.1 Cell Therapy Manufacturing: Installed Global Capacity in Terms of Number of Cleanrooms
12.2.1.1. Distribution by Size of Manufacturers
12.2.1.2. Distribution by Scale of Operation
12.2.1.3. Distribution by Location of Manufacturing Facilities
12.2.2. Cell Therapy Manufacturing: Installed Global Capacity in Terms of Cleanroom Area
12.2.2.1. Distribution by Size of Manufacturers
12.2.2.2. Distribution by Scale of Operation
12.2.2.3. Distribution by Location of Manufacturing Facilities
12.3. Key Assumptions and Methodology for Non-Industry Players
12.3.1. Cell Therapy Manufacturing: Installed Global Capacity in Terms of Number of Cleanrooms
12.3.1.1. Distribution by Scale of Operation
12.3.1.2. Distribution by Location of Manufacturing Facilities
12.3.2. Cell Therapy Manufacturing: Installed Global Capacity in Terms of Cleanroom Area
12.3.2.1. Distribution by Scale of Operation
12.3.2.2. Distribution by Location of Manufacturing Facilities
12.4 Concluding Remarks
13. COST PRICE ANALYSIS
13.1. Chapter Overview
13.2. Factors Contributing Towards High Price Tags of Cell-based Therapies
13.3. Pricing Models for Cell-based Therapies
13.3.1. On the Basis of Associated Costs for T-Cell Immunotherapies
13.3.2. On the Basis of Associated Costs for Stem Cell Therapies
13.3.3. On the Basis of Competition
13.3.4. On the Basis of Patient Segment
13.3.5. On the Basis of Expert Opinions
13.4. Cost Control for Cell Therapy Products
13.4.1. Cost of Goods Sold
13.4.2. Manufacturing Cost-Effective Therapies with Automation
13.4.3. Role of Cell Therapy Contract Manufacturing Organizations
14. MARKET SIZING AND FORECAST
14.1. Chapter Overview
14.2. Scope of the Forecast
14.3. Forecast Methodology
14.4. Input Tables and Key Assumptions
14.5. Overall Cell Therapy Manufacturing Market, 2018-2030
14.5.1. Cell Therapy Manufacturing Market, 2018-2030: Distribution by Type of Cell Therapy
14.5.2. Cell Therapy Manufacturing Market, 2018-2030: Distribution by Source of Cells
14.5.3. Cell Therapy Manufacturing Market, 2018-2030: Distribution by Scale of Operation
14.5.3. Cell Therapy Manufacturing Market, 2018-2030: Distribution by Purpose of
Manufacturing
14.5.4. Cell Therapy Manufacturing Market, 2018-2030: Distribution by Regions
14.6. Market Opportunity for Commercial Scale Manufacturing of Cell-based Therapies
14.6.1. Overall Commercial Scale Manufacturing Market for T-cell Therapies, 2018-2030
14.6.1.1. Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy)
14.6.1.2. Distribution by Source of Cells
14.6.1.3. Distribution by Regions
14.6.2. Overall Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2018-2030
14.6.2.1. Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy)
14.6.2.2. Distribution by Source of Cells
14.6.2.3. Distribution by Regions
14.6.3. Overall Commercial Scale Manufacturing Market for Stem Cell Therapies, 2018-2030
14.6.3.1. Distribution by Source of Cells
14.6.3.2. Distribution by Regions
14.7. Market Opportunity for Clinical Scale Manufacturing of Cell-based Therapies
14.7.1. Overall Clinical Scale Manufacturing Market for T-cell Therapies, 2018-2030
14.7.1.1. Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy)
14.7.1.2. Distribution by Source of Cells
14.7.1.3. Distribution by Regions
14.7.2. Overall Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2018-2030
14.7.2.1. Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy)
14.7.2.2. Distribution by Source of Cells
14.7.2.3. Distribution by Regions
14.7.3. Overall Clinical Scale Manufacturing Market for Stem Cell Therapies, 2018-2030
14.7.3.1. Distribution by Source of Cells
14.7.3.2. Distribution by Regions
15. KEY INSIGHTS
15.1. Chapter Overview
15.2. Cell Therapy Manufacturers: Grid Analysis
15.3. Cell Therapy Manufacturers: Logo Landscapes by Type of Cell Therapy
15.3.1. Immune Cells
15.3.2. Stem Cells
15.4. Cell Therapy Manufacturers: World Map Representation by Location of Manufacturing Facility
15.4.1. Industry Players
15.4.2. Non- Industry Players
16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors
16.7. Concluding Remarks
17. CONCLUSION
17.1. Owing to a Consistently Growing Pipeline, the Demand for Cell Therapy Manufacturing Services is Likely to Increase
17.2. The Market Features the Involvement of Several Industry, as well as Academic Players; this Trend is Anticipated to Persist in Future as well
17.3. Stakeholders have Established their Presence across Different Regions; Presently, the US and UK are Considered as Prominent Hubs for Cell Therapy Manufacturing
17.4. The Domain is Experiencing a Rise in Partnerships Activity, as Organizations Actively Collaborate to Develop Novel Technology Platforms and Improve Current Manufacturing Processes
17.5. Technical Advances Enabling Automation, Scale-up and Better Logistics Solutions are Expected to Act as Key Growth Drivers
17.6. Cell Therapy Manufacturing is Projected to become a Multi-Billion Dollar Market over the Coming Decade
18. SURVEY ANALYSIS
18.1. Chapter Overview
18.2. Seniority Level of Respondents
18.3. Type of Cell Therapy
18.4. Scale of Operation
18.5. Source of Cells
18.6. Type of Cell Culture System
18.7. Availability of Fill / Finish Services
19. INTERVIEW TRANSCRIPTS
19.1. Chapter Overview
19.2. Cell Therapies
19.2.1. Company Overview
19.2.2. Interview Transcript: Tim Oldham, Chief Executive Officer
19.3. Center for Commercialization of Cancer Immunotherapy / C3i
19.3.1. Company Overview
19.3.2. Interview Transcript: Arnaud Deladeriere, Manager, Business Development & Operations-cGMP Manufacturing Unit
19.4. CiMaas
19.4.1. Company Overview
19.4.2. Interview Transcript: Gerard MJ Bos, Chief Executive Officer
19.5. Lion TCR
19.5.1. Company Overview
19.5.2. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
19.6. Waisman Biomanufacturing
19.6.1. Company Overview
19.6.2. Interview Transcript: Brian Dattilo, Manager of Business Development
19.7. YposKesi
19.7.1. Company Overview
19.7.2. Interview Transcript: Mathilde Girard, Department Leader, Cell Therapy Innovation and Development
20. APPENDIX: TABULATED DATA
21. APPENDIX: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Classification of Advanced Therapy Medicinal Products
Figure 3.2 Steps for Manufacturing Cell Therapies
Figure 3.3 Centralized Manufacturing: Process Model
Figure 3.4 Decentralized Manufacturing: Process Model
Figure 3.5 Cell Therapy Manufacturing: Types of Manufacturers
Figure 3.6 Cell Therapies: Challenges and Drivers
Figure 3.7 Cell Therapies: Potency as Critical Quality Attribute
Figure 3.8 Cell Therapy Manufacturing: Supply Chain Model
Figure 3.9 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 4.1 Cell Therapy Manufacturers: Distribution by Location of Headquarters
Figure 4.2 Cell Therapy Manufacturers: Distribution by Location of Manufacturing Facility (Region-wise)
Figure 4.3 Cell Therapy Manufacturers: Distribution by Location of Manufacturing Facility (Country-wise)
Figure 4.4 Cell Therapy Manufacturers: Distribution by Type of Organization
Figure 4.5 Cell Therapy Manufacturers: Distribution by Type of Cells Manufactured
Figure 4.6 Cell Therapy Manufacturers: Distribution by Immune Cells
Figure 4.7 Cell Therapy Manufacturers: Distribution by Stem Cells
Figure 4.8 Cell Therapy Manufacturers: Distribution by Purpose of Production
Figure 4.9 Cell Therapy Manufacturers: Distribution by Scale of Operation
Figure 4.10 Cell Therapy Manufacturers: Distribution by Source of Cells
Figure 5.1 Cell Therapy Manufacturing: Distribution by Regulatory Authorities
Figure 6.1 Cell Therapy Manufacturing: Roadmap for the US
Figure 6.2 Cell Therapy Manufacturing: Roadmap for the Asia Pacific Economic Cooperation (APEC)
Figure 7.1 Probable Automation Approaches for Various Stages of Manufacturing Process
Figure 7.2 Cell Therapy Manufacturing: Types of Cell Therapy Manufacturing Systems
Figure 7.3 Requirements to Implement Closed Systems in Cell Therapy Manufacturing Processes
Figure 7.4 Advantages and Disadvantages of Single-Use System
Figure 7.5 Cell Therapy Manufacturing: Roadmap for Developing an Automated Device
Figure 7.6 Cell Therapy Manufacturing: Comparison Between Manual and Automated Processes
Figure 7.7 Cell Therapy Manufacturing: Comparative Analysis of Manual and Automated Processes Based on Affiliated Costs
Figure 7.8 Cell Therapy Manufacturing: Annual Comparison of Manual versus Automated Processes Based on Cost of Manufacturing per Batch
Figure 8.1 Brammer Bio: Service Portfolio
Figure 8.2 Cognate BioServices: Service Portfolio
Figure 8.3 FUJIFILM Cellular Dynamics: Service Portfolio
Figure 8.4 KBI Biopharma: Service Portfolio
Figure 8.5 PCT: Company Structure
Figure 8.6 PCT: Service Portfolio
Figure 8.7 Waisman Biomanufacturing: Service Portfolio
Figure 8.8 Waisman Biomanufacturing: Clinical Products Portfolio
Figure 8.9 Waisman Biomanufacturing: Quality Assurance and Control
Figure 8.10 Waisman Biomanufacturing: Manufacturing Suites
Figure 8.11 Waisman Biomanufacturing: Overview of Suite Services
Figure 8.12 BioNTech Innovative Manufacturing Services: Service Portfolio
Figure 8.13 Cell and Gene Therapy Catapult: Service Portfolio
Figure 8.14 CELLforCURE: Service Portfolio
Figure 8.15 Lonza: Historical Timeline
Figure 8.16 Lonza: Important Business Divisions
Figure 8.17 Lonza Pharma and Biotech: Service Portfolio
Figure 8.18 Lonza: Biological Manufacturing Services
Figure 8.19 Lonza: Cell-based Products
Figure 8.20 Lonza Netherlands: Service Portfolio
Figure 8.21 MaSTherCell: Service Portfolio
Figure 8.22 Roslin Cell Therapies: Service Portfolio
Figure 8.23 Cell Therapies: Service Portfolio
Figure 8.24 Cryosite: Service Portfolio
Figure 8.25 Japan Tissue Engineering: Service Portfolio
Figure 8.26 MEDINET: Service Portfolio
Figure 8.27 Nikon CeLL innovation: Service Portfolio
Figure 9.1 Center for Cell and Gene Therapy: Operating Segments
Figure 9.2 Center for Cell and Gene Therapy: Service Portfolio
Figure 9.3 Center for Cell Manufacturing Ireland: Service Portfolio
Figure 9.4 Molecular and Cellular Therapeutics: Service Portfolio
Figure 9.5 Newcastle Cellular Therapies Facility: Service Portfolio
Figure 11.1 Cell Therapy Manufacturing Partnerships: Cumulative Trend by Year (2014-2018)
Figure 11.2 Cell Therapy Manufacturing Partnerships: Distribution by Type of Partnership Model
Figure 11.3 Cell Therapy Manufacturing Partnerships: Distribution by Year and Type of Partnership Model (2014-2018)
Figure 11.4 Cell Therapy Manufacturing Partnerships: Distribution by Type of Cells
Figure 11.5 Cell Therapy Manufacturing Partnerships: Distribution by Most Active Players
Figure 11.6 Cell Therapy Manufacturing Partnerships: Regional Distribution
Figure 11.7 Cell Therapy Manufacturing: Regional Distribution by Intercontinental and Intracontinental Agreements
Figure 12.1 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Range of Installed Capacity
Figure 12.2 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Range of Installed Capacity
Figure 12.3 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Size of Manufacturers
Figure 12.4 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation
Figure 12.5 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Location of Manufacturing Facility
Figure 12.6 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Size of Manufacturers
Figure 12.7 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation
Figure 12.8 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Location of Manufacturing Facility
Figure 12.9 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Range of Installed Capacity
Figure 12.10 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Scale of Operation
Figure 12.11 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Location of Manufacturing Facility
Figure 12.12 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Range of Installed Capacity
Figure 12.13 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Scale of Operation
Figure 12.14 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Location of Manufacturing Facility
Figure 13.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 14.1 Overall Cell Therapy Manufacturing Market, Base Scenario, 2018-2030 (USD Million)
Figure 14.2 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy, 2018-2030 (USD Million)
Figure 14.3 Cell Therapy Manufacturing Market: Distribution by Source of Cells, 2018- 2030 (USD Million)
Figure 14.4 Cell Therapy Manufacturing Market: Distribution by Scale of Operation, 2018-2030 (USD Million)
Figure 14.5 Cell Therapy Manufacturing Market: Distribution by Purpose of
Manufacturing, 2018-2030 (USD Million)
Figure 14.6 Cell Therapy Manufacturing Market: Distribution by Regions, 2018 and 2030
Figure 14.7 Overall Commercial Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2018-2030 (USD Million)
Figure 14.8 Commercial Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2018-2030: Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy) (USD Million)
Figure 14.9 Commercial Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2018-2030: Distribution by Source of Cells (USD Million)
Figure 14.10 Commercial Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2018-2030: Distribution by Regions (USD Million)
Figure 14.11 Overall Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2018-2030 (USD Million)
Figure 14.12 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2018-2030: Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy) (USD Million)
Figure 14.13 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2018-2030: Distribution by Source of Cells (USD Million)
Figure 14.14 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2018-2030: Distribution by Regions (USD Million)
Figure 14.15 Overall Commercial Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2018-2030 (USD Million)
Figure 14.16 Commercial Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2018-2030: Distribution by Source of Cells (USD Million)
Figure 14.17 Commercial Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2018-2030: Distribution by Regions (USD Million)
Figure 14.18 Overall Clinical Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2018-2030 (USD Million)
Figure 14.19 Clinical Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2018-2030: Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy) (USD Million)
Figure 14.20 Clinical Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2018-2030: Distribution by Source of Cells (USD Million)
Figure 14.21 Clinical Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2018-2030: Distribution by Regions (USD Million)
Figure 14.22 Overall Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2018-2030 (USD Million)
Figure 14.23 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2018-2030: Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy) (USD Million)
Figure 14.24 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2018-2030: Distribution by Source of Cells (USD Million)
Figure 14.25 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2018-2030: Distribution by Regions (USD Million)
Figure 14.26 Overall Clinical Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2018-2030 (USD Million)
Figure 14.27 Clinical Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2018-2030: Distribution by Source of Cells (USD Million)
Figure 14.28 Clinical Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2018-2030: Distribution by Regions (USD Million)
Figure 15.1 Cell Therapy Manufacturers: Grid Analysis by Type of Manufacturer and Scale of Operation
Figure 15.2 Cell Therapy Manufacturers: Logo Landscape, Immune Cells
Figure 15.3 Cell Therapy Manufacturers: Logo Landscape, Stem Cells
Figure 15.4 Cell Therapy Manufacturers: Regional Distribution by Location of Manufacturing Facility, World Map Representation, Industry Players
Figure 15.5 Cell Therapy Manufacturers: Regional Distribution by Location of Manufacturing Facility, World Map Representation, Non-Industry Players
Figure 16.1 Cell Therapy Manufacturing: SWOT Analysis
Figure 16.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 17.1 Cell Therapy Manufacturing Market Forecast: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Figure 18.1 Survey Analysis: Distribution by Type of Organization
Figure 18.2 Survey Analysis: Distribution by Location of Manufacturing Facility
Figure 18.3 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 18.4 Survey Analysis: Distribution by Type of Cell Therapy
Figure 18.5 Survey Analysis: Distribution by Scale of Manufacturing
Figure 18.6 Survey Analysis: Distribution by Source of Cells
Figure 18.7 Survey Analysis: Distribution by Cell Culture System
Figure 18.8 Survey Analysis: Distribution by Fill / Finish Service
LIST OF TABLES
Table 3.1 Cell-based Therapies: Applications
Table 3.2 Differences between Cell Therapy and Biotechnology Products
Table 3.3 Cell-based Therapies: Commercialized Products
Table 3.4 Assessment Strategies for Different Manufacturing Processes
Table 3.5 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 4.1 List of Cell Therapy Manufacturers
Table 4.2 Cell Therapy Manufacturers: Type of Cells Manufactured
Table 4.3 Cell Therapy Manufacturers: Purpose of Production
Table 4.4 Cell Therapy Manufacturers: Scale of Operation
Table 4.5 Cell Therapy Manufacturers: Source of Cells
Table 4.6 Cell Therapy Manufacturers: Type of Cell Cultures
Table 4.7 Logistics Service Providers for Cell-based Therapies
Table 5.1 Cell Therapy Manufacturing: Regulatory Authorities
Table 5.2 Cell Therapy Manufacturing: Regulatory Considerations
Table 6.1 Cell Processing: Challenges and Strategies
Table 6.2 Cell Preservation, Distribution and Handling: Challenges and Strategies
Table 6.3 Process Monitoring and Quality Control: Challenges and Strategies
Table 6.4 Standardization and Regulatory Support: Challenges and Strategies
Table 6.5 Workforce Development: Challenges and Strategies
Table 6.6 Supply Chain and Transport Logistics: Challenges and Strategies
Table 7.1 Cell Therapy Manufacturing: List of Service Providers for Automation of Manufacturing Process
Table 7.2 Cell Therapy Manufacturing: Observed Changes in Scale-up Scenario while Switching from Manual to Automated Operations
Table 8.1 Brammer Bio: Company Overview
Table 8.2 Brammer Bio: Overview of Manufacturing Capabilities
Table 8.3 Brammer Bio: Partnerships
Table 8.4 Cognate BioServices: Company Overview
Table 8.5 Cognate BioServices: Overview of Manufacturing Capabilities
Table 8.6 Cognate BioServices: Partnerships
Table 8.7 FUJIFILM Cellular Dynamics: Company Overview
Table 8.8 FUJIFILM Cellular Dynamics: Overview of Manufacturing Capabilities
Table 8.9 FUJIFILM Cellular Dynamics: Partnerships
Table 8.10 KBI Biopharma: Company Overview
Table 8.11 KBI Biopharma: Overview of Manufacturing Capabilities
Table 8.12 PCT: Company Overview
Table 8.13 PCT: Overview of Manufacturing Capabilities
Table 8.14 PCT: Partnerships
Table 8.15 Waisman Biomanufacturing: Company Overview
Table 8.16 Waisman Biomanufacturing: Overview of Manufacturing Capabilities
Table 8.17 Waisman Biomanufacturing: Partnerships
Table 8.18 BioNTech Innovative Manufacturing Services: Company Overview
Table 8.19 BioNTech Innovative Manufacturing Services: Overview of Manufacturing Capabilities
Table 8.20 BioNTech Innovative Manufacturing Services: Partnerships
Table 8.21 Cell and Gene Therapy Catapult: Company Overview
Table 8.22 Cell and Gene Therapy Catapult: Overview of Manufacturing Capabilities
Table 8.23 Cell and Gene Therapy Catapult: Partnerships
Table 8.24 CELLforCURE: Company Overview
Table 8.25 CELLforCURE: Overview of Manufacturing Capabilities
Table 8.26 CELLforCURE: Partnerships
Table 8.27 Lonza: Company Overview
Table 8.28 Lonza: Global Manufacturing Sites
Table 8.29 Lonza: Overview of Manufacturing Capabilities
Table 8.30 Lonza: Partnerships
Table 8.31 MaSTherCell: Company Overview
Table 8.32 MaSTherCell: Overview of Manufacturing Capabilities
Table 8.33 MaSTherCell: Partnerships
Table 8.34 Roslin Cell Therapies: Company Overview
Table 8.35 Roslin Cell Therapies: Overview of Manufacturing Capabilities
Table 8.36 Roslin Cell Therapies: Partnerships
Table 8.37 Cell Therapies: Company Overview
Table 8.38 Cell Therapies: Overview of Manufacturing Capabilities
Table 8.39 Cell Therapies: Partnerships
Table 8.40 Cryosite: Company Overview
Table 8.41 Cryosite: Overview of Manufacturing Capabilities
Table 8.42 Cryosite: Partnerships
Table 8.43 Japan Tissue Engineering: Company Overview
Table 8.44 Japan Tissue Engineering: Overview of Manufacturing Capabilities
Table 8.45 Japan Tissue Engineering: Partnerships
Table 8.46 MEDINET: Company Overview
Table 8.47 MEDINET: Overview of Manufacturing Capabilities
Table 8.48 Nikon CeLL innovation: Company Overview
Table 8.49 Nikon CeLL innovation: Overview of Manufacturing Capabilities
Table 8.50 Nikon CeLL innovation: Partnerships
Table 8.51 WuXi AppTec: Company Overview
Table 8.52 WuXi AppTec: Overview of Manufacturing Capabilities
Table 8.53 WuXi AppTec: Partnerships
Table 9.1 Center for Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
Table 9.2 Center for Cell Manufacturing Ireland: Overview of Manufacturing Facilities and Capabilities
Table 9.3 Clinical Cell and Vaccine Production Facility: Overview of Manufacturing Facilities and Capabilities
Table 9.4 Guy’s and St. Thomas GMP Facility: Overview of Manufacturing Facilities and Capabilities
Table 9.5 Laboratory of Cell and Gene Medicine: Overview of Manufacturing Facilities and Capabilities
Table 9.6 Molecular and Cellular Therapeutics: Overview of Manufacturing Facilities and Capabilities
Table 9.7 Newcastle Cellular Therapies Facility: Overview of Manufacturing Facilities and Capabilities
Table 9.8 Rayne Cell Therapy Suite: Overview of Manufacturing Facilities and Capabilities
Table 9.9 Scottish National Blood Transfusion Services: Overview of Manufacturing Services and Capabilities
Table 9.10 Sydney Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
Table 10.1 Cell Therapy Manufacturing: List of Non-Profit Organizations
Table 10.2 CellCAN: Overview
Table 10.3 Cell Therapy Manufacturing Cooperative Research Center: Overview
Table 10.4 National Cell Manufacturing Consortium: Overview
Table 10.5 California Institute of Regenerative Medicine: Overview
Table 10.6 Cell Therapy Manufacturing: List of Gene and Cell Therapy Societies
Table 11.1 Cell Therapy Manufacturing: List of Collaborations
Table 12.1 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms: Average Capacity by Size of Manufacturers (Sample Data Set for Industry Players)
Table 12.2 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry): Distribution by Size of Manufacturers
Table 12.3 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area: Average Capacity by Size of Manufacturers (Sample Data Set for Industry Players)
Table 12.4 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry): Distribution by Size of Manufacturers
Table 12.5 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms: Average Capacity for Non-Industry Players
Table 12.6 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area: Average Capacity for Non-Industry Players
Table 13.1 Costs Associated with Manufacturing of Stem Cell Therapies
Table 13.2 Price of Marketed Gene and Cell Therapies
Table 13.3 Price of Marketed Targeted Drugs
Table 13.4 Expert Opinions on Pricing of T-Cell Immunotherapies
Table 14.1 Active Clinical Studies for Cell Therapies
Table 14.2 Active Clinical Studies for Cell Therapies: Distribution by Patients Enrolled
Table 14.3 Number of Active Clinical Trials for Cell Therapies, 2018-2030
Table 14.4 Number of Active Clinical Trials for Cell Therapies, 2018-2030: Distribution by Patients Enrolled
Table 18.1 Survey Response: Overview of the Participating Organizations
Table 18.2 Survey Response: Seniority Level of Respondents
Table 18.3 Survey Response: Type of Cell Therapy
Table 18.4 Survey Response: Scale of Operation
Table 18.5 Survey Response: Source of Cells
Table 18.6 Survey Response: Cell Culture System
Table 18.7 Survey Response: Fill / Finish Service
Table 19.1 Center for Commercialization of Cancer Immunotherapy: Company Snapshot
Table 19.2 CiMaas: Company Snapshot
Table 19.3 Lion TCR: Company Snapshot
Table 19.4 YposKesi: Company Snapshot
Table 20.1 Cell Therapy Manufacturers: Distribution by Location of Headquarters
Table 20.2 Cell Therapy Manufacturers: Distribution by Location of Manufacturing Facility (Regions-wise)
Table 20.3 Cell Therapy Manufacturers: Distribution by Location of Manufacturing Facility (Countries-wise)
Table 20.4 Cell Therapy Manufacturers: Distribution by Type of Organization
Table 20.5 Cell Therapy Manufacturers: Distribution by Type of Cell Therapy
Table 20.6 Cell Therapy Manufacturers: Distribution by Immune Cells
Table 20.7 Cell Therapy Manufacturers: Distribution by Stem Cells
Table 20.8 Cell Therapy Manufacturers: Distribution by Purpose of Production
Table 20.9 Cell Therapy Manufacturers: Distribution by Scale of Operation
Table 20.10 Cell Therapy Manufacturers: Distribution by Source of Cells
Table 20.11 Cell Therapy Manufacturing: Distribution by Regulatory Authorities
Table 20.12 Cell Therapy Manufacturing: Comparative Analysis of Manual versus Automated Processes Based on Cost of Manufacturing per Batch
Table 20.13 Cell Therapy Manufacturing Partnerships: Cumulative Trend of by Year (2014-2018)
Table 20.14 Cell Therapy Manufacturing Partnerships: Distribution by Type of Partnership Model
Table 20.15 Cell Therapy Manufacturing Partnerships: Distribution by Year and Type of Partnership Model (2014-2018)
Table 20.16 Cell Therapy Manufacturing Partnerships: Distribution by Type of Cells
Table 20.17 Cell Therapy Manufacturing Partnerships: Distribution by Most Active Players
Table 20.18 Cell Therapy Manufacturing Partnerships: Regional Distribution
Table 20.19 Cell Therapy Manufacturing: Regional Distribution by Intercontinental and Intracontinental Agreements
Table 20.20 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry): Distribution by Size of Manufacturers
Table 20.21 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry): Distribution by Scale of Operation
Table 20.22 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry): Distribution by Location of Manufacturing Facility
Table 20.23 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry): Distribution by Size of Manufacturers
Table 20.24 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry): Distribution by Scale of Operation
Table 20.25 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry): Distribution by Location of Manufacturing Facility
Table 20.26 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry): Distribution by Scale of Operation
Table 20.27 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry): Distribution by Location of Manufacturing Facility
Table 20.28 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Non-Industry): Distribution by Scale of Operation
Table 20.29 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Non-Industry): Distribution by Location of Manufacturing Facility
Table 20.30 Overall Cell Therapy Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 20.31 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy, 2018-2030 (USD Million)
Table 20.32 Cell Therapy Manufacturing Market: Distribution by Source of Cells, 2018-2030 (USD Million)
Table 20.33 Cell Therapy Manufacturing Market: Distribution by Scale of Operation, 2018- 2030 (USD Million)
Table 20.34 Cell Therapy Manufacturing Market: Distribution by Purpose of Manufacturing, 2018-2030 (USD Million)
Table 20.35 Cell Therapy Manufacturing Market: Distribution by Regions, 2018 and 2030
Table 20.36 Overall Commercial Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 20.37 Commercial Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy) (USD Million)
Table 20.38 Commercial Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Source of Cells (USD Million)
Table 20.39 Commercial Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Regions (USD Million)
Table 20.40 Overall Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 20.41 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy) (USD Million)
Table 20.42 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Source of Cells (USD Million)
Table 20.43 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Regions (USD Million)
Table 20.44 Overall Commercial Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 20.45 Commercial Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Source of Cells (USD Million)
Table 20.46 Commercial Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Regions (USD Million)
Table 20.47 Overall Clinical Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 20.48 Clinical Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy) (USD Million)
Table 20.49 Clinical Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Source of Cells (USD Million)
Table 20.50 Clinical Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Regions (USD Million)
Table 20.51 Overall Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 20.52 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy) (USD Million)
Table 20.53 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Source of Cells (USD Million)
Table 20.54 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Regions (USD Million)
Table 20.55 Overall Clinical Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 20.56 Clinical Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Source of Cells (USD Million)
Table 20.57 Clinical Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios, 2018-2030: Distribution by Regions (USD Million)
Table 20.58 Survey Analysis: Distribution by Type of Organization
Table 20.59 Survey Analysis: Distribution by Location of Manufacturing Facility
Table 20.60 Survey Analysis: Distribution by Seniority Level of Respondents
Table 20.61 Survey Analysis: Distribution by Type of Cell Therapy
Table 20.62 Survey Analysis: Distribution by Scale of Manufacturing
Table 20.63 Survey Analysis: Distribution by Source of Cells
Table 20.64 Survey Analysis: Distribution by Cell Culture System
Table 20.65 Survey Analysis: Distribution by Fill / Finish Service

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report